DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
MINNEAPOLIS, March 18, 2019 (GLOBE NEWSWIRE) — DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March 19th. DiaMedica’s management will host a live ... [Read]
DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) — DiaMedica Therapeutics Inc. (Nasdaq:DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz Carlton, Laguna Niguel in Dana Point, CA. ... [Read]
UPDATE — DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) — DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSXV:DMA) announced today that the U.S. Food and Drug Administration (“FDA”) has accepted DiaMedica’s Investigational New Drug application (“IND”) for the initiation of ... [Read]